Features | Partner Sites | Information | LinkXpress
Sign In
Ampronix
Schiller
GLOBETECH PUBLISHING LLC

Molecular Imaging Tracers Help Determine Brain Metastases Treatment Strategies

By Medimaging International staff writers
Posted on 17 Dec 2013
Imaging with the molecular imaging tracer 18F-FDOPA (L-3,4-dihydroxy-6-[18F]fluoro-phenylalanine) can help differentiate radiation-induced lesions from new tumor growth in patients who have been treated with radiotherapy for brain metastases, according to new research.

Using this amino acid tracer, researchers discovered that physicians could effectively differentiate the two types of lesions 83% of the time. Progression-free survival could also be predicted through evaluating the 18F-FDOPA imaging findings.

Brain metastases occur in 20%–40% of all cancer patients, especially in those with melanoma, non-small-cell lung cancer, and breast cancer. They account for 170,000 new cases yearly in the United States alone, and prognosis is poor. Treatment for brain metastases usually includes a combination of surgery, radiation treatment, and chemotherapy.

“Histopathological changes in neural tissue treated with radiation could trigger clinical and imaging manifestations which are very similar to those caused by tumor growth,” said Karlo J. Lizarraga, MD, MS, from the department of neurology, Miller School of Medicine, University of Miami (FL, USA), and lead author of the study. “The challenge is then to differentiate whether these manifestations are due to radiation or to tumor progression or recurrence. Accurate and timely distinction between these two possibilities can significantly affect patient care, and outcome for treatment modalities are completely different for each case.”

In the retrospective study, published ahead of print October 28, 2013, and slated for the January 1, 2014, issue of the Journal of Nuclear Medicine, researchers analyzed images from 32 patients who had 83 earlier irradiated brain metastases and who underwent 18F-FDOPA positron emission tomography (PET). The studies were analyzed both semi-quantitatively and visually to determine whether lesions were caused by radiation injury or were recurrent or progressive brain metastases. Results were verified by histopathologic analysis or clinical follow-up. The prognostic ability of 18F-FDOPA in predicting progression-free survival and overall survival was also studied with the Kaplan-Meier and Cox regression techniques.

The best overall accuracy for differentiating between the two types of lesions was achieved using visual scoring, which had a sensitivity of 81.3%, a specificity of 84.3%, and an overall accuracy of 83.1%. The semi-quantitative analysis resulted in a sensitivity of 81.3%, a specificity of 72.5% and an overall accuracy of 75.9%.

Researchers also discovered that evaluations with 18F-FDOPA PET was highly prognostic of progression-free survival, as lesions with a negative PET result had a mean time to progression that was 4.6 times longer than lesions with positive 18F-FDOPA PET findings. Moreover, a trend toward predicting overall survival was also seen.

18F-FDOPA PET imaging is currently available in few centers. The longer physical half-life of 18F-FDOPA, when compared to other amino acid tracers, gives it the advantage of potential automated production and transport to PET centers for widespread use,” noted Dr. Lizarraga.

Related Links:

Miller School of Medicine, University of Miami



Channels

Radiography

view channel

Brain Imaging Study Identifies Biological Differences Between PTSD and Traumatic Brain Injuries

The results of a study intended to help identify the biological differences, and treatment options for Post-Traumatic Stress Disorder (PTSD) and Traumatic Brain Injury (TBI) have been published in the April 2015 special US Veterans Issue of the journal Brain Imaging and Behavior. The research team which included brain-imaging... Read more

MRI

view channel
Image: The ViewRay MRIdian System (Photo courtesy of ViewRay).

Unique MRI-Guided Radiation Therapy System Showcased at ESTRO 2015

ViewRay (Cleveland OH, USA) has demonstrated their advanced radiation therapy technology for the treatment of cancer at the April, 2015, European Society for Therapeutic Radiology and Oncology (ESTRO)... Read more

Ultrasound

view channel

Ultrasound Device Reduces the Number of Tests Required for Inpatients and Outpatients

The results of a study carried out by the European Association for the Study of the Liver (EASL; Geneva, Switzerland) into the use of a Pocket-sized Ultrasound Device (PUD) together with a physical examination, have been presented at the 2015 International Liver Congress, in Vienna (Austria). The study evaluated the... Read more

General/Advanced Imaging

view channel

Global Healthcare Study of Coronary Artery Disease Reaches Significant Milestone

A major milestone has been reached in the Lipid-Rich Plaque (LRP) study, a prospective, multicenter clinical trial with the potential to reveal breakthrough correlations between Lipid-Rich Plaques and occurrence of heart attacks. The LPR study has now enrolled 1,000 patients, and aims to identify a correlation between... Read more

Imaging IT

view channel

Childhood Radiation Exposure Can Be Reduced Significantly Using EMR Decision Support

The results of a study to find ways to reduce the pediatric radiation burden have been published in the May 8, 2015, issue of the Journal of the American Board of Family Medicine. The study included 115 physicians from 17 US military family medicine training programs, and aimed to find whether an existing clinical decision... Read more

Industry News

view channel

Medical Imaging Company Recognized for Focus on Customer Partnerships

A company is recognized for excellence in its growth strategy and implementation, a high degree of product and technology innovation, and leadership. Frost & Sullivan (Mountain View, CA, USA) has awarded the 2015 North American Frost & Sullivan Medical Imaging Company of the Year award to Toshiba America Medical... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.